Nuvation Bio Inc. (NUVB) is in Healthcare, Biotechnology, based in United States, listed on NYSE. Market cap 1.74B USD. 52-week range 3.36 to 9.75 USD. Data as of 2026-10-09.
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against ...